Background
==========

Lung cancer is the leading cause of cancer-related death in China \[[@b1-medscimonit-23-247]\], of which 85% are non-small cell lung cancer (NSCLC). During the last decades, the treatments for advanced NSCLC were confined to platinum-based chemotherapy, with an unsatisfactory response rate of 30% \[[@b2-medscimonit-23-247]\]. Intensive studies on tumor-related aberrant signaling pathways have led to rapid development in the treatment of lung cancer. Medicines targeted at epidermal growth factor receptor (EGFR) gene mutation or anaplastic lymphoma kinase fusion gene increase the response rate to 65--80% \[[@b3-medscimonit-23-247],[@b4-medscimonit-23-247]\], whereas tumor progression is still unavoidable eventually. With a median progression-free survival of about 10 months and a poor overall survival (OS), patients with advanced NSCLC need new therapeutic targets.

Fibroblast growth factor receptor 1 (FGFR1), a transmembrane tyrosine kinase receptor of fibroblast growth factors (FGFs), is encoded by *FGFR1* gene (8p11--12). After combining with FGFs, FGFR ligand-dependent dimerization activates tyrosine kinase domains, resulting in the phosphorylation of intracellular tyrosine residues \[[@b5-medscimonit-23-247]\]. Phosphorylated tyrosine residues work as docking sites for adaptor proteins, such as Grb2, SOS protein, recruiting Ras-guanosine diphosphate (Ras-GDP), activating mitogen-activated protein kinase, protein kinase C, phosphatidylinositol 3-kinase/AKT pathway, and signal transducer and activator of transcription signaling pathways \[[@b6-medscimonit-23-247]\]. FGFRs regulate cell proliferation, differentiation, antiapoptosis, and angiogenesis \[[@b7-medscimonit-23-247]\]. The overexpression of FGFR1 was found in NSCLC and recognized as a novel therapeutic target. Its expression status, however, is less studied in the Chinese population. Although several meta-analyses have been reported, the correlation between the expression status of FGFR1 and clinical pathological features remains controversial \[[@b8-medscimonit-23-247]--[@b10-medscimonit-23-247]\]. This study focused on these issues and also studied the promotion of angiogenesis with VEGFR2, which is the main receptor of VEGF-A that plays an important role in neoangiogenesis \[[@b11-medscimonit-23-247]\]. The expression of VRGFR2 can be detected in a variety of tumor cells, including colorectal cancer \[[@b12-medscimonit-23-247]\], breast cancer \[[@b13-medscimonit-23-247]\], and non-small cell lung cancer \[[@b14-medscimonit-23-247]\]. The overexpression of VEGFs and VEGFR2 is related to tumor invasion and metastasis, mainly because of their effect on angiogenesis \[[@b15-medscimonit-23-247],[@b16-medscimonit-23-247]\]. Studies have shown interaction between FGF-FGFR and VEGF-VEGFR signaling pathways. FGF can upregulate the expression of VEGF, FGFR, and VEGFR in epithelial cells, and VEGF can upregulate the expression of FGF \[[@b17-medscimonit-23-247],[@b18-medscimonit-23-247]\]. It is widely known that tumor development and metastasis depend on neoangiogenesis \[[@b19-medscimonit-23-247]\]. Prior studies indicated that neoangiogenesis is essential in developing lung cancer, and microvessel density (MVD) is increased even in premalignant lesions and early-stage lung cancer \[[@b20-medscimonit-23-247],[@b21-medscimonit-23-247]\]. In this retrospective study, the correlation between FGFR1 and clinical features was explored, including survival analysis and promotion of angiogenesis by FGFR1 and VEGFR2.

Material and Methods
====================

Patients and specimens
----------------------

This was a retrospective study. Ninety-two patients pathologically diagnosed with NSCLC, who received radical resection (pneumonectomy + lymph node dissection) in West China Hospital of Sichuan University from July 2006 to July 2008 were enrolled in the study. The exclusion criteria were as follows: received neoadjuvant chemotherapy and/or radiotherapy; received EGFR tyrosine kinase inhibitors; had another kind of carcinoma; loss to follow-up; and histopathological specimens unavailable. The study was approved by the Hospital Ethics Committees, and all the patients enrolled gave informed consent. Follow-up data were obtained by telephone and/or outpatient department visits. The patients underwent chest computed tomography (CT) scan, abdomen CT scan, and brain magnetic resonance imaging, and also bone single-photon emission computed tomography if necessary, during periodic follow-up visit according to the National Comprehensive Cancer Network (NCCN) guideline. Staging was based on the NCCN guideline, and histological grading was evaluated according to the World Health Organization criteria. The clinical features included age, gender, stage, histological type, grade, lymph node status, smoking status, and postoperative adjuvant therapy. The primary endpoint was OS, and the secondary endpoint was recurrence-free survival (RFS).

Immunohistochemical staining
----------------------------

Formalin-fixed and paraffin-embedded surgical specimens were immunostained according to streptavidin-peroxidase protocol. The paraffin-embedded tissues were sliced up into slices of 4 μm. Then, after deparaffinization and antigen retrieval, the tissue sections were incubated with FGFR1 antibodies (monoclonal rabbit anti-human, 1:500, Cell Signaling Technology Co., Ltd, MA, USA), VEGFR2 antibodies (polyclonal rabbit anti-human, 1:100, Golden Bridge Biotechnology Co., Ltd., Beijing, China), and CD34 antibodies (monoclonal mouse anti-human, 1:100, Golden Bridge Biotechnology Co., Ltd, Beijing, China) at 37°C for 1 h, and then at 4°C overnight. The next day the sections were rinsed 3 times with phosphate-buffered saline (PBS) before incubating with biotinylated goat anti-rabbit antibodies (1:200, Golden Bridge Biotechnology Co., Ltd, Beijing, China) and subsequently with horseradish-labeled streptavidin (1:200, Golden Bridge Biotechnology Co., Ltd., Beijing, China) at 37°C for 40 min. 3,3′-Diaminobenzidine was used as a chromogen and hematoxylin as a counterstain. Positive controls were provided by reagent companies, and PBS instead of primary antibodies was used as negative control.

Evaluation criteria
-------------------

Brownish-black or brown particles displayed in certain places were defined as a specific positive reaction. The weighted score, evaluated in a semi-quantitative way, was calculated by multiplying the quantity score by staining intensity score, representing FGFR1 and VEGFR2 expression levels \[[@b22-medscimonit-23-247],[@b23-medscimonit-23-247]\]. The quantity scores based on the percentage of stained cells were defined as follows: 0 for \<5% cells stained; 1 for 5--25% cells stained; 2 for 26--50% cells stained; 3 for 51--75% cells stained; and 4 for ≥76% cells stained. The staining intensity was scored 0--3: 0 for no staining; 1 for pale yellow staining; 2 for brown staining; and 3 for brownish-black staining. Weighted score ≤1, 2--3, 4--6, or ≥7 was defined as negative, weak, moderate, or strong, respectively. For statistical analysis, the subgroups were finally dichotomized into high expression (moderate and strong) and low expression (negative and weak). CD34 was detected by immunostaining for MVD (24). The hot spots (intratumoral areas with a high density of CD34-positive vessels) were identified under low-power fields, while the CD34-positive vessels in hot spots were quantitated under high-power fields case by case. The average value of 5 fields was defined as the MVD for each sample. All the specimens were evaluated by 2 pathologists independently.

Statistical analysis
--------------------

SPSS 16.0 software (SPSS Inc., IL, USA) was used for statistical analysis. The correlations between the expression of FGFR1and VEGFR2, MVD, and clinicopathological features were tested by chi-square test, t test, and Spearman's rank correlation coefficient, respectively. Kaplan-Meier curve was used to analyze the correlation between the expression of FGFR1 and VEGFR2, MVD, and prognosis. Univariate and multivariate analyses were performed by Cox regression model. A *P* value less than 0.05 was considered to be statistically significant.

Results
=======

Clinical characteristics
------------------------

A total of 92 patients (70 males and 22 females) with a mean age of 58.5 (range 38--79) years were enrolled in the study. Classified by histological type, 49 patients had squamous lung cancer, 37 had adenocarcinoma, 4 had adenosquamous carcinoma, and 2 had large-cell lung cancer. Histologically, 54 samples were poorly differentiated, 36 moderately differentiated, and 2 well differentiated. According to the NCCN guideline of 2013, 25 patients were at stage I, 16 were at stage II, 42 were at stage III, and 9 were at stage IV. Moreover, 59 of all the patients were continuously smoking (defined as never quit or quit for less than 1 year), and 33 patients were nonsmokers or quit for more than 1 year.

Expression of FGFR1, VEGFR2, and CD34 in NSCLC
----------------------------------------------

Both FGFR1 and VEGFR2 were mainly expressed in the cytoplasm ([Figure 1A, 1B](#f1-medscimonit-23-247){ref-type="fig"}). In terms of FGFR1 expression, 25% (23/92) were negative, 48.9% (45/92) were weak, 18.5% (17/92) were moderate, and 7.6% (7/92) were strong. The high expression of FGFR1 was observed in 26.1% (24/92) of samples. Notably, the high expression rate of FGFR1 was significantly higher in squamous lung cancer than in adenocarcinoma ([Table 1](#t1-medscimonit-23-247){ref-type="table"}. 36.7% *vs.* 16.2%, *P*=0.036). The high expression of FGFR1 was not correlated with smoking (23.7% *vs.* 30.3%, *P*=0.491), while in statistical analysis, we found that the expression rate (patients that had been tested to be positive, including weak, moderate and strong) of FGFR1 was significantly higher in smoking patients (84.7% *vs.* 60.6%, *P*=0.009). Moreover, 5.4% (5/92) of samples were VEGFR2 negative, 52.2% (48/92) were weak, 29.3% (27/92) were moderate, and 13% (12/92) were strong. The high expression of VEGFR2 was detected in 43.4% (39/92) of samples. Patients with lymph node metastasis (*P*=0.022) and those with tumor size more than 4 cm (*P*=0.001) had higher expression of VEGFR2. The high expression of FGFR1 and VEGFR2 was not correlated with the patients' age, gender, smoking status, differentiation, and stage. Microvascular endothelial cells could be stained yellow or brownish by CD34 antibody ([Figure 1C](#f1-medscimonit-23-247){ref-type="fig"}). The number of stained endothelial cells in a certain area was defined as MVD. In this study, the average MVD was 34.6. Patients with lymph node metastasis (37.5±10.7 *vs.* 31.0±10.3, *P*=0.004) and stages III--IV (36.9±10.7 *vs.* 31.7±10.5, *P*=0.024) presented with a significantly higher MVD in tumor tissues, while no correlation was found between MVD and gender, age, smoking status, histological type, and differentiation.

Correlations among the expression of MVD, FGFR1, and VEGFR2
-----------------------------------------------------------

MVD was significantly higher in patients with high expression of VEGFR2 than in patients with low expression of VEGFR2 (40.6±11.0 *vs.* 30.1±8.7, *P*\<0.001), and a higher MVD was associated with the high expression of FGFR1 as well (43.1±10.1 *vs.* 31.5±9.6, *P*\<0.001). The Spearman rank correlation analysis ([Table 2](#t2-medscimonit-23-247){ref-type="table"}) demonstrated that, to some extent, the expression intensity of VEGFR2 (*r*=0.224, *P*=0.032) and FGFR1 (*r*=0.265, *P*=0.011) was positively correlated with MVD. In addition, the expression levels of FGFR1 and VEGFR2 were significantly positively correlated (*r*=0.619, *P*\<0.001).

Impact of FGFR1, VEGFR2, and MVD on prognosis
---------------------------------------------

With a total follow-up of 80 months, the patients with the high expression of FGFR1 presented with a significantly shorter OS (23.5 months *vs.* 39.8 months, *P*=0.043) and RFS (15.0 months *vs.* 28.0 months, *P*=0.043) than those with the low expression of FGFR1 ([Figure 2A, 2B](#f2-medscimonit-23-247){ref-type="fig"}). The expression level of VEGFR2 showed no significant impact on the survival of patients with NSCLC. Notably, in squamous lung cancer, the OS in patients with the high expression of VEGFR2 was 32.5 months, which was shorter than that in patients with the low expression (51.0 months, *P*=0.028) ([Figure 2E](#f2-medscimonit-23-247){ref-type="fig"}). However, no significant difference was observed in the survival of patients with adenocarcinoma between high-expression and low-expression groups of VEGFR2 (*P* = 0.918) ([Figure 2F](#f2-medscimonit-23-247){ref-type="fig"}). The analysis of the impact of MVD on OS and RFS is shown in [Figure 2C and 2D](#f2-medscimonit-23-247){ref-type="fig"}. The RFS of patients with a high and a low value of MVD was 18.1 and 30.4 months (*P*=0.010), respectively, while the OS in the low-MVD group was significantly longer than the OS in the high-MVD group (51.0 months *vs.* 32.5 months, *P*=0.013).

Univariate and multivariate analyses
------------------------------------

All clinical and pathological features, including gender, age, smoking status, tumor size, differentiation, histological type, lymph node status, stage, adjuvant therapy, FGFR1 expression, VEGFR2 expression, and MVD value, were considered in the Cox regression model. The univariate analysis showed that tumor stage (*P*\<0.001), lymph node metastasis (*P*=0.003), high expression of FGFR1 (*P*=0.043), and high value of MVD (*p*=0.013) in tumor tissue suggested shorter OS, while only stage (stage III: hazard ratio \[HR\] 3.451, 95% confidence interval \[CI\]: 1.621--7.345, *P*=0.001; stage IV: HR 39.207, 95% CI: 12.201--125.986, *P*\<0.001) and high expression of FGFR1 (HR 2.194,95% CI: 1.232--3.908,*P*=0.008) remained independent risk factors of OS in multivariate analysis. Adjuvant chemotherapy was the protection factor for OS (HR 0.492, 95% CI: 0.251--0.964, *P*=0.039) ([Table 3](#t3-medscimonit-23-247){ref-type="table"}).

Considering that stage is universally thought to be the most important prognostic factor, stratified analysis based on stages was done ([Figure 3](#f3-medscimonit-23-247){ref-type="fig"}). The OS was not significantly different between low- and high-expression of FGFR1 in stage I, II, III and IV, respectively, while when the patients with stage I and II were all taken into account, the OS was significantly longer in those with low FGFR1 expression than high FGFR1 expression (*P*=0.044). No significant difference was observed in the survival of patients with low and high FGFR1 expression in stage III--IV (*P*=0.253).

Discussion
==========

Understanding the molecular alterations in lung cancer might provide better choices for targeted therapy. The malfunction of FGFR signaling pathway, mainly caused by the overexpression and/or mutation of receptor genes, was found in a variety of epithelial tumors \[[@b25-medscimonit-23-247]--[@b28-medscimonit-23-247]\], such as breast cancer, prostatic cancer, oral carcinoma, and gastric cancer. Both *in vitro* and *in vivo* experiments showed that the FGFR signal pathway played an important role in growth, survival, and migration of lung cancer cells, which could be blocked by FGFR tyrosine kinase inhibitor \[[@b29-medscimonit-23-247],[@b30-medscimonit-23-247]\]. Previous studies compared the results between fluorescence *in situ* hybridization and immunohistochemistry (IHC) in detecting the overexpression of FGFR1, where no significant difference was detected between the 2 methods \[[@b31-medscimonit-23-247]\]. In this study, the expression of FGFR1 by IHC, and its correlation with VEGFR2 and MVD, was analyzed to evaluate its correlation with clinical features and the impact on prognosis.

According to previous reports, gene amplification of FGFR1 was about 16--20% in squamous lung cancer and 5% in adenocarcinoma. Inconsistently, researches from Weiss \[[@b32-medscimonit-23-247]\] and Schildhaus \[[@b33-medscimonit-23-247]\] showed no FGFR1 gene amplification in adenocarcinoma. Related researches were less conducted China. Several common histological types, such as squamous lung cancer, adenocarcinoma, large-cell lung cancer, and adenosquamous carcinoma, were included in this study. The present study showed that 2 patients with large-cell lung cancer and 4 with adenosquamous carcinoma had FGFR1 negative or weak expression. FGFR1 expression was significantly higher in squamous lung cancer than in adenocarcinoma (36.7% *vs.* 16.2%, *P*=0.036), which was consistent with most previous reports \[[@b31-medscimonit-23-247],[@b34-medscimonit-23-247]\]. The similarity between these results implicated no significant ethnic diversity in the FGFR1 status while large-scale researches are still in need. The expression rate of FGFR1 was slightly higher in this study than in previous reports, which might be due to different detection methods. For example, a newly published research using reverse transcription-polymerase chain reaction showed an extremely higher amplification rate of FGFR1 (41.5% in squamous lung cancer and 14.3% in nonsquamous lung cancer) than in any other researches. IHC is a widely used method in detecting the expression of specific proteins, which could test the expression of FGFR1. The standard method has not been identified yet. Zhang's research showed that FGFR1 inhibitor induced tumor stasis or regression in the FGFR1-amplified NSCLC model \[[@b29-medscimonit-23-247]\]. This study demonstrated that FGFR1 was overexpressed in some NSCLCs, especially in squamous lung cancer in the Chinese population, suggesting that FGFR1 might be a potential target for targeted therapy and its inhibitor might be applied for the treatment of squamous lung cancer and a small part of adenocarcinoma harboring the high expression of FGFR1.

It is widely known that EGFR mutation frequently emerges in Asian female nonsmokers. Some studies suggested that smoking was also positively correlated with FGFR1 amplification \[[@b31-medscimonit-23-247]\], while some did not \[[@b34-medscimonit-23-247]\]. This study showed some differences, as the high expression of FGFR1 was not correlated with smoking (23.7% *vs.* 30.3%, *P*=0.491), while the expression rate of FGFR1 was significantly higher in smoking patients (84.7% *vs.* 60.6%, *P*=0.009). In conclusion, no correlation was found between high expression of FGFR1 and clinical characteristics such as age, gender, stage, grade, smoking status, and lymph node metastasis, suggesting no special predictive potential of these clinical characteristics for FGFR1 status in patients with NSCLC. Weiss \[[@b32-medscimonit-23-247]\] demonstrated that gene amplification of FGFR1 led to poor prognosis. Conversely, Trans \[[@b35-medscimonit-23-247]\] demonstrated that FGFR1 amplification suggested a longer survival. Inconsistent pathological types and different EGFR-TKI treatment status in analysis might explain the differing results. In this study, patients who had taken EGFR-TKI after relapse were excluded, and multivariate analysis was used to identify the correlation between FGFR1 expression and clinical features. It showed that the high expression of FGFR1 was related to poor prognosis, which was consistent with the findings of Weiss's research. However, in Weiss's study, clinical pathological characteristics (e.g., stage, smoking status, and adjuvant chemotherapy) were not taken into consideration. The present study, using multivariate analysis (including gender, age, smoking status, tumor size, degree of differentiation, lymph node metastasis, stage, and adjuvant chemotherapy), demonstrated that patients with high expression of FGFR1 had shorter RFS and OS, suggesting that the high expression of FGFR1 was the independent prognostic indicator of NSCLC. We also took stage, the most important prognostic factor, into account. Although we found no significant difference in survival between low and high FGFR1 expression in stage I, II, III, and IV, when we combined the patients with stage I and II, the OS was significantly longer in those with low FGFR1 expression than high FGFR1 expression (*P*=0.044). No significant difference was observed in the survival of patients with low- and high-FGFR1 expression in stage III--IV (*P*=0.253), indicating that the prognostic value could be more important in early stage of lung cancer. The small sample size may be why we did not get statistical significance in stage I and II separately.

VEGFR2 expression, mainly located in the cytoplasm, was found in most tumor tissues (94.6%) in this study, which was consistent with Decaussin's report \[[@b36-medscimonit-23-247]\]. The expression of VEGFR2 was not influenced by age, gender, smoking status, stage, or grade, but it was significantly higher in patients with lymph node metastasis (*P*=0.022) and/or tumor size more than 4 cm (*P*=0.001). Some studies suggested that the expression status of VEGFR2 was correlated with prognosis \[[@b37-medscimonit-23-247]\]. Seto's study \[[@b38-medscimonit-23-247]\], involving 60 postsurgery patients with stage I lung cancer, indicated that patients with VEGFR2 expression in tumor cells presented with poorer survival, while some other studies showed no correlation between VEGFR2 expression and prognosis \[[@b39-medscimonit-23-247]\]. A recent meta-analysis found no statistically significant effect of VEGFR2 expression on survival, but VEGFA/VEGFR2 co-expression had an influence on survival (40). The differences might be caused by the diversity in stage, histological type, period of follow-up, and sample size between different studies. The present study showed no correlation between the expression statuses of VEGFR2 and RFS and OS in patients with NSCLC after surgery. The subgroup analysis, however, showed that in a subgroup of squamous lung cancer, patients with the high expression of VEGFR2 had shorter RFS and OS compared with the low-expression group (*P*=0.028; *P*=0.033), while this correlation was not found in adenocarcinoma. According to the literature, similar results were found in the Holzer's study \[[@b41-medscimonit-23-247]\]. In other words, the expression status of VEGFR2 might play different roles in the prognosis of different histological types. In the meantime, it reflected indirectly that carcinomas with different histological types present with different biological characteristics, so that personalized treatment should be emphasized during treatment.

VEGF/VEGFR signal and FGF/FGFR signal play crucial roles in angiogenesis. The proangiogenic effect of VEGF and bFGF is mediated through the VEGF receptor 2 and FGF receptor 1, respectively. Previous researches also showed crosstalk between them *in vitro* and *in vivo* \[[@b42-medscimonit-23-247]\]. In this study, MVD, which reflected the number of vessels, was significantly higher in tumors with the high expression of VEGFR2 than in tumors with the low expression of VEGFR2. The same situation was found in the case of FGFR1. The present study, using human tumor tissues, verified in terms of histopathology that the expression of FGFR1 and VEGFR2 was significantly correlated (r=0.619), and both of them had more or less positive correlation with MVD (r=0.224; r=0.265). Although the sample size was small, this study found and verified some important findings in China. The role of FGFR1 in squamous lung cancer and its crosstalk with VEGFR2 in tumor development need to be explored further. It is hoped that FGFR1 would serve as one of the treatment targets in NSCLC, especially in squamous lung cancer.

Conclusions
===========

The high expression of FGFR1 existed in part of NSCLC (including squamous lung cancer and adenocarcinoma) and was the independent prognostic factor associated with poor prognosis, especially in early stages. The expression of FGFR1 and VEGFR2 was positively correlated, and both of them were associated with angiogenesis.
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![Immunohistological staining of FGFR1 and VEGFR2, and MVD in NSCLC. (**A**) Expression of FGFR1. (**B**) Expression of VEGFR2; FGFR1 and VEGFR2 antibodies were mainly stained in the cytoplasm. (**C**) Microvascular endothelial cells were stained yellow or brownish by CD34 antibody.](medscimonit-23-247-g001){#f1-medscimonit-23-247}

![Overall survival (OS) and recurrence-free survival (RFS) curves for patients with NSCLC. (**A**) The OS in FGFR1 low- and high-expression groups; a significant difference can be seen (*P*=0.043). (**B**) The RFS was significantly different between FGFR1 low- and high-expression groups (*P*=0.043). (**C**) The OS was significantly longer in the group with MVD \<35 than in the group with MVD ≥35 (*P*=0.013). (**D**) The RFS was significantly longer in the group with MVD \<35 than in the group with MVD ≥35 (*P*=0.010). (**E**) In squamous lung cancer, the OS was shorter in patients with the high expression of VEGFR2 than in the low-expression group (51.0 months, *P*=0.028). (**F**) No significant difference was observed in the survival of patients with adenocarcinoma between the high- and low-expression groups of VEGFR2 (*P*=0.918).](medscimonit-23-247-g002){#f2-medscimonit-23-247}

![Overall survival (OS) curves for patients with NSCLC in different stages. (**A**) The OS in stage I; no significant difference can be seen (*P*=0.093). (**B**) The OS was not significantly different between FGFR1 low- and high-expression groups in stage II (*P*=0.170). (**C**) The OS was not significantly longer in the group with low FGFR1 expression in stage III (*P*=0.269). (**D**) The OS was not significantly longer in the group with low FGFR1 expression in stage IV (*P*=0.088). (**E**) The OS was significantly longer in the group with low FGFR1 expression in stage I--II (*P*=0.044). (**F**) No significant difference was observed in the survival of patients with low and high FGFR1 expression in stage III--IV (*P*=0.253).](medscimonit-23-247-g003){#f3-medscimonit-23-247}

###### 

The correlation between the expression of FGFR1, VEGFR2, MVD, and clinicopathological features.

  Clinical features       Total   FGFR1 high expression   VEGFR2 high expression   MVD                             
  ----------------------- ------- ----------------------- ------------------------ ----------- ------- ----------- -------
  Gender                                                                                                           
   Male                   70      18 (25.7)               0.885                    27 (38.6)   0.186   33.6±10.3   0.139
   Female                 22      6 (27.3)                                         12 (54.5)           37.6±12.7   
  Age (year)                                                                                                       
   \<60                   51      10 (19.6)               0.114                    18 (35.3)   0.124   33.8±11.2   0.497
   ≥60                    41      14 (34.1)                                        21 (51.2)           35.4±10.8   
  Smoke                                                                                                            
   Yes                    59      14 (23.7)               0.491                    25 (42.4)   0.996   38.1±11.9   0.058
   No                     33      10 (30.3)                                        14 (42.4)           33.1±10.6   
  Tumor size                                                                                                       
   \<4 cm                 47      11 (23.4)               0.549                    12 (25.5)   0.001   35.9±10.5   0.261
   ≥4 cm                  45      13 (28.9)                                        27 (60.0)           33.4±11.3   
  Histopathology                                                                                                   
   Squamous               49      18 (36.7)               0.036                    21 (42.9)   0.593   34.0±11.9   0.380
   Adenocarcinoma         37      6 (16.2)                                         18 (48.6)           36.2±9.7    
  Grade                                                                                                            
   Poor                   54      14 (25.9)               0.967                    21 (38.9)   0.418   35.1±10.4   0.575
   Moderate/well          38      10 (26.3)                                        18 (47.4)           33.8±11.9   
  Lymph node metastasis                                                                                            
   Yes                    51      12 (23.5)               0.533                    27 (52.9)   0.022   37.5±10.7   0.004
   No                     41      12 (29.3)                                        12 (29.3)           31.0±10.3   
  Stage                                                                                                            
   I--II                  41      11 (26.8)               0.884                    13 (31.7)   0.063   31.7±10.5   0.024
   III--IV                51      13 (25.5)                                        26 (51.0)           36.9±10.9   
  Adjuvant therapy                                                                                                 
   Yes                    69      16 (23.2)               0.273                    28 (40.6)   0.543   33.2±11.1   0.495
   No                     23      8 (34.8)                                         11 (42.4)           35.0±10.9   

###### 

The correlation between FGFR1, VEGFR2, and MVD.

                                              VEGFR2      MVD       FGFR1
  ----------------- ------------------------- ----------- --------- -----------
  VEGFR2            Correlation coefficient   1.000       0.224\*   0.619\*\*
  Sig. (2-tailed)   .                         0.032       \<0.001   
  N                 92                        92          92        
  MVD               Correlation coefficient   0.224\*     1.000     0.265\*
  Sig. (2-tailed)   0.032                     .           0.011     
  N                 92                        92          92        
  FGFR1             Correlation coefficient   0.619\*\*   0.265\*   1.000
  Sig. (2-tailed)   \<0.001                   0.011       .         
  N                 92                        92          92        

###### 

Univariate and multivariate analyses with regard to RFS and OS (n=92).

  Variable                Total No.   Univariate analysis       Multivariate Cox regression   
  ----------------------- ----------- ------------------------- ----------------------------- -------
  Gender                                                                                      
   Male                   70          0.830                                                   
   Female                 22                                                                  
  Age (year)                                                                                  
   \<60                   51          0.662                                                   
   ≥60                    41                                                                  
  Smoke                                                                                       
   Yes                    59          0.742                                                   
   No                     33                                                                  
  Tumor size                                                                                  
   \<4 cm                 47          0.095                                                   
   ≥4 cm                  45                                                                  
  Grade                                                                                       
   Poor                   54          0.536                                                   
   Moderate or well       38                                                                  
  Histopathology                                                                              
   Squamous               49          0.593                                                   
   Adenocarcinoma         37                                                                  
  Lymph node metastasis                                                                       
   Yes                    51          0.003                                                   
   No                     41                                                                  
  Stage                                                                                       
   I                      25          \<0.001                                                 
   II                     16                                                                  
   III                    42          3.451 (1.621,7.345)       0.001                         
   IV                     9           39.207 (12.201,125.986)   \<0.001                       
  Adjuvant therapy                                                                            
   Yes                    69          0.708                     0.492 (0.251,0.96)            0.039
   No                     23                                                                  
  FGFR1 expression                                                                            
   Low                    68          0.043                     2.194 (1.232,3.908)           0.008
   High                   24                                                                  
  VEGFR2 expression                                                                           
   Low                    53          0.174                                                   
   High                   39                                                                  
  MVD                                                                                         
   \<35                   47          0.013                                                   
   ≥35                    45                                                                  

HR -- hazard risk; CI -- confidence interval.
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